

Demographic and Clinical Characteristics of the Severe Covid-19 Infections: First Report from Mashhad University of Medical Sciences, Iran

Running title: Characteristics of Covid-19 in Iran

Ladan Goshayeshi^{1,2, †}, Mina Akbari Rad^{3, †}, Robert Bergquist⁴, Abolghasem Allahyari³, members of the MUMS Covid-19 Research Team⁵, Benyamin Hoseini^{6,7, *}

Members of the MUMS Covid-19 Research Team: Kamila Hashemzadeh, Nasrin Milani, Mahdi Gholian-Aval, Fariba Rezaeitalab, Mohammad Jafar Sadeghi Quchani, Zahra Nahbandani, Zahra Javid, Mahnaz Mozdourian, Mohammad Ali Yaghoubi, Zahra Mozaheb, Mohsen Seddigh-Shamsi, Mohammad Moeini Nodeh, Shima Nabavi, Mandana Khodashahi, Hooman Mosannen Mozaffari, Mohammadreza Farzanehfaz, Zahra Lotfi, Alireza Shariati, Shekoofe Bonakdaran, Zahra Rezaieyazdi, Zahra Mirfeizi, Maryam Miri, Reza Bassiri, Sajjad Ataei Azimi

¹Department of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

²Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

³Department of internal medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

⁴Ingerod, SE-454 94 Brastad, Sweden; Formerly UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, Geneva, Switzerland.

⁵A full list of the research team members is provided in Supplementary Note online.

⁶Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

⁷Department of Health Information Technology, Neyshabur University of Medical Sciences, Neyshabur, Iran.

[†]Ladan Goshayeshi and Mina Akbari Rad contributed equally as joint lead authors.

***Corresponding author: Benyamin Hoseini**, Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Health Information Technology, Neyshabur University of Medical Sciences, Neyshabur, Iran; Tel: +985143306219, Cellphone: +989127858864; Email: Hoseinib1@num.ac.ir.

۳۴ **Abstract**

۳۵ *Background.* Coronavirus Disease 2019 (Covid-19) is expanding worldwide. The characteristics of this infection in
۳۶ patients varies from country to country. To move forward, clinical data on infected patients are needed. Here, we
۳۷ report a comparison between fatalities and recovery of patients with severe Covid-19, based on demographic and
۳۸ clinical characteristics.

۳۹ *Methods.* Between 5 March and 12 May 2020 in Mashhad, Iran, 1,278 of 4,000 suspected Covid-19 patients were
۴۰ confirmed positive by real-time reverse-transcriptase–polymerase-chain-reaction assay of upper respiratory
۴۱ specimens. We compared the demographic, exposure history and clinical symptoms of 925 survivors and 353 fatal
۴۲ cases with confirmed disease.

۴۳ *Results.* Mean (SD) age for all confirmed patients was 56.9 (18.7) years, 67.1 (15.9) years in fatal cases and 53.0
۴۴ (18.3) years in survivors. Multivariable logistic regression analysis showed that the outcome of patients was associated
۴۵ with age (OR = 1.049, P = 0.0001, 95% CI = 1.040–1.057). Despite a high burden of Covid-19 infections in the 30-
۴۶ 39 and 40-49 year age groups, most of these (89.6% and 87.2%, respectively) recovered. The median (IQR) duration
۴۷ of hospitalization was 9.0 (6.0-14.0) days. The most prevalent co-morbidities were cardiovascular disorders (21%)
۴۸ and diabetes (16.3%). Dyspnoea (72.7%), cough (68.1%) and fever (63.8%) were the most frequent clinical symptoms.
۴۹ Healthcare workers, of whom two (3%) died, comprised 5.2% of infected-cases. Combination antiviral and antibiotic
۵۰ therapy was used in 43.0% of cases.

۵۱ *Conclusions.* The characteristics of severe Covid-19 varied substantially between fatal cases and survivors, with
۵۲ diabetes and cardiovascular disorders the most prevalent co-morbidities. In contrast to other studies, there were a
۵۳ higher number of fatalities in younger patients in our settings.

۵۴
۵۵ **Keywords.** COVID-19, SARS-COV-2; Epidemiological characteristics; symptoms, Iran

۵۶
۵۷
۵۸

Background

In late 2019, the city of Wuhan, Hubei Province, China became the centre of an unusual pneumonia-like disease of an unknown cause [1-4]. In December 2019, Chinese scientists realized that this condition was caused by a novel Coronavirus, first called 2019-nCoV [5, 6]. On January 7, 2020, scientists isolated this novel type of Coronavirus from the sputum of these patients, which was on February 11, 2020 classified as Severe Acute Respiratory Syndrome Coronavirus type two (SARS-CoV-2) by the International Committee on Taxonomy of Viruses [6, 7]. On the same date, the World Health Organization (WHO) named the disease caused by this virus coronavirus disease 2019 (Covid-19) in the International Classification of Diseases [6]. As of March 11, 2020 when the Covid-19 outbreak had spread worldwide and reached 118,319 confirmed cases and 4,292 confirmed deaths, WHO declared it a global pandemic [8-10]. The initial source of Covid-19 is still unknown, but it is now confirmed that the first known case of this disease was linked to the Huanan seafood market of Wuhan City, which was closed on January 1, 2020 to control the situation [4, 11].

SARS-CoV-2 is a member of the Coronaviridae family that consists of a single-stranded positive-sense RNA [4]. So far, two human infections by viruses related to Coronaviridae family are known: the Severe Acute Respiratory Syndrome (SARS), caused by SARS-CoV, which emerged in China in 2002 and spread across 37 countries, and the Middle-East Respiratory Syndrome (MERS), caused by MERS-CoV, which was first seen in Saudi Arabia in 2012 [4]. There were two separate outbreaks of SARS in the period 2002-2004, while cases of MERS still occur though only rarely [12]. SARS-COV-2 is genetically related to SARS-CoV with both of them being beta-coronaviruses [13, 14].

The clinical manifestation of Covid-19 varies from asymptomatic infection to severe viral pneumonia with multisystem failure leading to death [3, 15, 16]. The most common clinical manifestations include, but are not limited to, fever, non-productive cough, myalgia, fatigue and dyspnoea. Chest radiography shows bilateral lung infiltrations indicative of pneumonia and laboratory indices include increased erythrocyte sedimentation rate and C-Reactive protein and, lymphopenia [15, 17]. In severe cases, acute respiratory distress syndrome, acute cardiac and kidney injury and shock can occur, which may lead to irreversible organ failure and death [17].

By May 16, 2020, there were 4,602,900 confirmed cases with 307,135 confirmed deaths globally, translating into a case fatality rate (CFR) of 6.67%. At this date, there were 116,635 confirmed cases with 6,902 deaths in Iran resulting

٨٦ in the same CFR ([WHO](#) daily report). We aimed to describe the characteristics of patients with Covid-19 in Razavi
٨٧ Khorasan, a province in Iran which has a population of 6.5 million. Herein, we report demographic and clinical
٨٨ characteristics of patients with severe Covid-19 in Mashhad, the second largest city in Iran and capital of Razavi
٨٩ Khorasan.

٩٠

٩١ **Materials and methods:**

٩٢ We undertook a retrospective cross-sectional study of consecutive Covid-19 patients diagnosed between 5 March and
٩٣ 12 May 2020 in Mashhad, Iran. Data were collated by the centre for Diseases Prevention and Control of Mashhad
٩٤ University of Medical Sciences. Severe illness usually begins approximately 1 week after the onset of symptoms.
٩٥ Dyspnea is the most common symptom of severe disease and is often accompanied by hypoxemia [6, 17]. Patients
٩٦ with severe Covid-19 should be hospitalized for careful monitoring. In our study all cases were symptomatic and 94%
٩٧ of the cases were inpatients from hospitals affiliated to Mashhad University of Medical Sciences. Thus, we called
٩٨ these cases in this study as sever Covid-19. Among 4,000 mostly severe cases suspected to be infected that had
٩٩ undergone further investigation, 1,278 (32.0%) were confirmed as true Covid-19 cases by real-time reverse-
١٠٠ transcriptase–polymerase-chain-reaction (RT-PCR) assay of nasal and/or pharyngeal swabs. Clinical and
١٠١ demographic results of laboratory-confirmed cases were included in a review of exposure history, health outcomes
١٠٢ and symptoms. Admission to an intensive care unit (ICU) or the use of mechanical ventilation within this cohort with
١٠٣ severe symptoms were the primary end-points of the study. Secondary end-point included duration of hospitalization,
١٠٤ history of infection (defined as the time from onset of symptom(s) until discharge from the hospital or death), and
١٠٥ outcome (dead or recovered). Fever was defined as axillary temperature $>37.5^{\circ}\text{C}$. Prescribed medications included
١٠٦ lopinavir/ritonavir, antibiotics, and oseltamivir.

١٠٧ **Statistics Analysis**

١٠٨ Categorical variables were summarized as frequencies and percentages. The Shapiro–Wilk test was used to evaluate
١٠٩ normality of data. Normally distributed data were expressed as mean \pm standard deviation (SD), and skewed data as
١١٠ median and interquartile range (IQR). Two-tailed Student’s t and Mann–Whitney U tests were used to compare
١١١ grouped continuous variable data where appropriate. Chi-square and Fisher’s exact tests were used to perform

112 intergroup and categorical comparisons as appropriate. Logistic regression was performed to multivariable analysis,
113 comparing deceased and recovered patients. Reported p-values of <0.05 were considered statistically significant. SPSS
114 software, version 16 (SPSS Inc., Chicago, IL, USA) was used to analyse the data.

115

116 **Results:**

117 *Demographic characteristics.* Of the 1,278 confirmed Covid-19 patients, 353 (27.6%) died and 925 recovered.
118 Mean (SD) age for confirmed patients was 56.9 (18.7) years, for deceased cases 67.1 (15.9) years and for recovered
119 cases 53.0 (18.3) years. There was a statistically significant association between age and mortality with the mortality
120 rate rising with age (Table 1). Multivariable logistic regression analysis also showed that the outcome of patients was
121 associated with age (OR = 1.049, P = 0.0001, 95% CI = 1.040–1.057), when adjusted for gender, therapeutic approach,
122 body temperature, and duration of hospitalization. Considering age as categorical variable (≤ 50 vs. >50 years),
123 multivariable logistic regression revealed that odds of death among patients >50 years was more than that among those
124 ≤ 50 years (OR = 4.7, P = 0.0001, 95% CI = 3.4–6.5). Despite the high frequency of Covid-19 infections accrued in
125 the 30-39 and 40-49 age groups, most of them (130/145 = 89.6 and 170/195 = 87.2%, respectively) recovered (Table
126 1; Fig. 1). Twenty-six (2.0 %) of all 1,278 confirmed cases were <20 years old, and 28 (2.2%) were >89 years (Fig.
127 1). Most (793/1,278 = 62%) of the confirmed patients were males, however there was no statistically significant
128 difference in outcomes with reference to gender (Table 1).

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

۱۴۸
۱۴۹

Table 1. Association between Covid-19 status and outcomes

Variable investigated		Outcome Number (%)		P-value
		Deceased (n = 353)	Recovered (n = 925)	
Continuous age - mean (SD)		67.1 (15.9)	53.0 (18.3)	0.0001
Age (categorical)	0-9	1 (0.3)	12 (1.3)	0.0001
	10-19	1 (0.3)	12 (1.3)	
	20-29	4 (1.1)	66 (7.1)	
	30-39	15 (4.2)	130 (14.1)	
	40-49	25 (7.1)	170 (18.4)	
	50-59	47 (13.3)	193 (20.9)	
	60-69	104 (29.5)	165 (17.8)	
	70-79	74 (21.0)	102 (11.0)	
	80-89	62 (17.6)	67 (7.2)	
	90-99	19 (5.4)	8 (0.9)	
	100-109	1 (0.3)	0 (0.0)	
Gender	Female	129 (36.5)	356 (38.5)	0.52
	Male	224 (63.5)	569 (61.5)	
Therapeutic approach	Antiviral & antibiotic	149 (42.2)	401 (43.4)	0.08
	Conservative	71 (20.1)	139 (15.0)	
	Antiviral	133 (37.7)	385 (41.6)	
Specific medication used	Lopinavir/ritonavir and antibiotic ^a	131 (37.1)	120 (13.0)	NA
	Oseltamivir ^b	222 (62.9)	805 (87.0)	
Body temperature (C°) - mean (SD)		37.6 (0.76)	37.7 (0.73)	0.09
Hospitalization (days) - median (IQR)		9.0 (6.0-14.0)	9.0 (6.0-14.0)	0.18

^aprescribed for severe cases; ^bprescribed for mild cases; NA= Not applicable.

۱۵۰
۱۵۱
۱۵۲




Fig 1. The frequency of the severe Covid-19 infections in different age groups.

103

104

100

106 *Patient end-points.*

107 Of 1,278 patients, 151 (11.8 %) were admitted to ICU of which 70 (46.3%) demised. Furthermore, of 1,278 cases,
 108 499 (39.0%) underwent mechanical ventilation of which 176 (35.3%) demised (Table 2). The median (IQR) duration
 109 of hospitalization was 9.0 (6.0-14.0) days, with no significant difference in duration of hospitalization between those
 110 that recovered and those who died (Table 1).

111

112 *Co-morbidities and symptoms.* The most frequent co-morbidities were cardiovascular disorders (268/1,278; 21.0%)
 113 and diabetes (208/1,278; 16.3%). Dyspnoea (929, 72.7%), cough (870, 68.1%), and fever (815, 63.8%) were the most
 114 frequent clinical symptoms (Table 2). Overall, 1,251/1,278 (97.9%) of the cases had at least one clinical symptom.

165 Compared with survivors, deceased cases showed a higher rate of co-morbidities including cardiovascular disorders
 166 (28.3% vs. 18.2%), diabetes (22.9% vs. 13.7%) and chronic respiratory disorders (8.2% vs. 3.0%) (Table 2).

167

168

Table 2. Frequency of co-morbidities and symptoms due to COVID-19 infections

Frequency Co-morbidity	Frequency (%)		
	Among all infected cases (n= 1,278)	Among deceased cases (n= 353)	Among recovered cases (n= 925)
Cardiovascular disorder	268 (21.0)	100 (28.3)	168 (18.2)
Diabetes	208 (16.3)	81 (22.9)	127 (13.7)
Liver disorders	45 (3.5)	18 (5.1)	27 (2.9)
Kidney disorders	40 (3.1)	19 (5.4)	21 (2.3)
Chronic resp. disorder	57 (4.5)	29 (8.2)	28 (3.0)
Acute resp. distress syndrome (ARDS)	13 (1.02)	4 (1.1)	9 (0.1)
Mild pneumonia	136 (10.64)	24 (6.8)	112 (12.1)
Symptom			
Fever	815 (63.8)	244 (69.1)	571 (61.7)
Cough	870 (68.1)	229 (64.9)	641 (69.3)
Dyspnoea	929 (72.7)	287 (81.3)	642 (69.4)
General malaise	247 (19.3)	61 (17.3)	186 (20.1)
Myalgia	199 (15.6)	49 (13.9)	150 (16.2)
Confusion	87 (6.8)	41 (11.6)	46 (5.0)
Sore throat	152 (11.9)	31 (8.8)	121 (13.0)
Diarrhoea	47 (3.7)	11 (3.1)	36 (3.9)
Nausea & vomiting	113 (8.8)	27 (7.6)	86 (9.3)
Headache	114 (8.1)	24 (6.8)	90 (9.7)
End-points			
ICU admission	151 (11.8)	70 (19.8)	81 (8.7)
Using mechanical ventilation	499 (39.0)	176 (49.8)	323 (34.9)
Other			
Exposure or visit to hospital within the last 14 days	131 (10.2)	38 (10.7)	93 (10.0)
Contact with a respiratory patients in the last 14 days	616 (48.2)	126 (35.7)	490 (53.0)

169

170

171 ***Therapeutic approach***

172 Most patients (550/1,278; 43%) received antiviral and antibiotic combination therapy, 518/1,278 (40.5%) received
 173 antiviral therapies only, and 210/1,278 (16.5%) did not receive antiviral or antibiotic therapy. No significant
 174 differences in the treatment approach between patients that died and those that recovered were observed (Table 1).

175 Mortality rates associated with lopinavir/ritonavir and antibiotic combination therapy and oseltamivir therapy were
 176 37.1% and 62.9%, respectively (Table 1).

۱۷۷

۱۷۸ Of the 1,278 confirmed cases, 67 (5.2%) were healthcare workers, of whom 2 (3.0%) died. Thirty-one (46.3%) of
۱۷۹ these healthcare workers were presumed to have been infected through occupational exposure to infected patients.
۱۸۰ Cough (77.6%), fever (68.7) and dyspnoea (56.7%) were the commonest symptoms in healthcare workers with Covid-
۱۸۱ 19. Six (9.0%) had comorbidities (cardiovascular disorders, n=3; diabetes, n=3). Seven (10.4%) of the healthcare
۱۸۲ workers required mechanical ventilation and 6 were admitted to ICU.

۱۸۳

۱۸۴ **Discussion**

۱۸۵ This is the first study from Mashhad, Iran, to report the characteristics of patients with severe confirmed Covid-19.
۱۸۶ Increasing age was associated with an increased risk of mortality. The most frequent co-morbidities were
۱۸۷ cardiovascular disorders and diabetes, and the most frequent symptoms were dyspnoea, cough, and fever. The highest
۱۸۸ burden of disease clustered in the 50-59 and 60-69 year age groups, while the highest CFR was patients aged 80-89
۱۸۹ years. These findings are in line with previous reports [6, 18].

۱۹۰

۱۹۱ Mean (SD) age of Iranian Covid-19 patients in our study was 56.9 (18.7) years, which is similar to other studies [17,
۱۹۲ 19, 20], but older than that reported by Guan et al. [2] in china who reported a median age (IQR) of 47.0 (35.0 - 58.0)
۱۹۳ years, with 55.1% of their cases were between 15-49 years, and younger than the median of 64 years reported in other
۱۹۴ studies [4, 21]. Although, the most frequent Covid-19 infection occurred in the 50-59 and 60-69 age groups in our
۱۹۵ study, the frequency of infection was also considerable in the 30-39 and 40-49 year age groups. The high frequency
۱۹۶ of Covid-19 infection in these age groups may be due to the low median age (30 years) of the Iranian population
۱۹۷ and/or due to inclusion of mainly working-age population in this age group [22]. It seems that the frequency of Covid-
۱۹۸ 19 infections rises considerably from age group of 50-59 years [23, 24]. In contrast to findings in China and Italy [6,
۱۹۹ 25], we found a considerably higher proportion of fatalities in the age groups panning the range from 20-50 years.
۲۰۰ This high proportion of fatalities in young people may be due to differences in life expectancy of different countries
۲۰۱ [26]. For lower- and middle-income countries, the proportion of deaths among younger age groups appears
۲۰۲ substantially larger. Another reason for this high proportion of fatalities in young people may be due to unknown co-
۲۰۳ morbidities of these people. Elderly people with known co-morbidities may take more care of themselves than young

20.4 people with unknown co-morbidities. Also, it may be due to shortage of ICU that caused some patients were
20.5 mechanically ventilated in ordinary wards, i.e. outside ICU.

20.6

20.7 In our study, the prevalence of the Covid-19 infection was higher among men (62%) compared with the reports of
20.8 China (49.3% - 54.3%) [17, 21]. However, our finding of male predominance in severe cases was similar to reports
20.9 from Italy (60%) [27], and the United States (63%) [4].

21.0

21.1 Huang et al [18] reported a CFR of 15% among hospitalized Covid-19 cases in China. According to the WHO daily
21.2 report, the crude CFR was 5.6% in China by May 10, 2020. At the beginning of the Covid-19 outbreak in Italy, the
21.3 crude CFR was 11.8% (12,430/105,792) [28], but this decreased as the number of cases increased. In our study, RT-
21.4 PCR testing was only used for symptomatic cases, including more severely ill patients at a high risk of mortality. This
21.5 selection bias, and the fact that our study describes outcomes in confirmed cases during a comparatively short window
21.6 of time, limits our ability to arrive at accurate estimates of CFR relating Covid-19 in our setting. Long-term screening
21.7 of all population at risk should facilitate reporting of more reliable CFR estimates in future studies. Estimation of the
21.8 infection fatality rate (IFR) would also be of interest, but would require reliable antibody detection assay and large
21.9 population-based samples.

22.0

22.1 According to WHO interim clinical guidance (Rev. March 20, 2020) [29], fever, cough, fatigue and anorexia are the
22.2 most common signs of Covid-19 and our findings comply with this. However, in our study dyspnoea (72.7%) was
22.3 twice as prevalent compared to WHO estimates (31-40%) [29]. Prevalence of dyspnoea in our study, was similar to
22.4 that from United States, however [4, 30]. The prevalence of dyspnoea in China complies with the WHO guidelines
22.5 [19, 21, 31], although they may also be slightly higher [32]. The WHO should update the information on symptoms
22.6 and signs of Covid-19 based on new global data, pointing out that there may be differences with respect to region.

22.7

22.8 Cardiovascular disorders (21%) and diabetes (16.3%) were the most prevalent co-morbidities among Covid-19
22.9 patients in our study. Previous studies have reported diverse prevalence rates for cardiovascular disorders (11-45%)
23.0 and diabetes (13-35%) [4, 19, 30, 33]. Meta-analyses report pooled prevalence of 8.4% and 12% for cardiovascular

۲۳۱ disorders, and 8.0% to 9.7% for diabetes [34, 35]. Assessing the association between patients' awareness of Covid-19
۲۳۲ and risk factors for severe disease and adherence to prevention protocols should be evaluated in future studies.

۲۳۳
۲۳۴ The fatality rate among healthcare workers was 3% in our study, considerably higher than that reported in China
۲۳۵ (0.33%) [36]. This may be due to a shortage of personal protective equipment (PPE) at the early stages of the Covid-
۲۳۶ 19 pandemic in Iran. Future studies should focus on the impact that availability of PPE had on CFR among healthcare
۲۳۷ workers in Iran, and other countries.

۲۳۸
۲۳۹ Huang et al [37] reported that 32% of patients were admitted to ICU, whereas in our study only 11.8% received ICU
۲۴۰ care. The fatality rate among patients treated in ICU was 46.3% in our study, lower than that (78%) reported by Zhou
۲۴۱ et al. [6]. All patients admitted to ICU received broad-spectrum antibiotics and antiviral medications, a combination
۲۴۲ that may have contributed to the lower mortality rate in our setting. Importantly, the use if the RT-PCR testing of all
۲۴۳ ICU-admitted patients strengthened the reliability of CFR estimates of this category of patients.

۲۴۴
۲۴۵ To our knowledge, this is the first study to address the characteristics of Covid-19 patients confirmed by RT-PCR in
۲۴۶ Mashhad, Iran. However, it has limitations, chiefly in that the RT-PCR testing approach focused on cases with severe
۲۴۷ symptoms, most of which were hospitalized. We analysed data from patients treated in facilities served by the
۲۴۸ Mashhad University of Medical Sciences, and so did not cover all areas of Razavi Khorasan, although most patients
۲۴۹ requiring hospitalization are routinely referred to this city. Despite the above-mentioned limitations, we feel that our
۲۵۰ findings are instructive and will inform future research, both in Iran and internationally.

۲۵۱
۲۵۲ In summary, the frequency of Covid-19 fatalities rose considerably from 30-39 years, with a higher number of fatalities
۲۵۳ in younger patients than in international studies. Fever, cough, and dyspnoea were common symptoms among
۲۵۴ hospitalized patients with Covid-19. Diabetes and cardiovascular disorders were the most prevalent co-morbidities,
۲۵۵ as observed in other studies.

۲۵۶
۲۵۷ **List of abbreviations:**
۲۵۸ Covid-19: Coronavirus Disease 2019

۲۵۹ SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

۲۶۰ SARS: severe acute respiratory syndrome

۲۶۱ ICU: intensive care unit

۲۶۲ RT-PCR: real-time reverse-transcriptase polymerase chain reaction

۲۶۳

۲۶۴ **Declarations**

۲۶۵ *Ethics approval.* This study was approved by the Ethics Committee of the Mashhad University of Medical Science
۲۶۶ (Ethics code: IR.MUMS.REC.1398.308).

۲۶۷ *Consent for publication.* Not applicable.

۲۶۸ *Availability of data and materials.* The datasets used and/or analysed during the current study are available from the
۲۶۹ corresponding author on reasonable request.

۲۷۰ *Competing interests.* The authors declare that they have no competing interests.

۲۷۱ *Funding.* This work was supported by Mashhad University of Medical Sciences (grant number of 981800).

۲۷۲ *Authors' contributions.* BH, RB designed the study design. All authors contributed in data gathering and
۲۷۳ interpretation of the results. LG, MAR, BH wrote the first draft of the manuscript. RB edited final version of the
۲۷۴ manuscript. All authors read, commented and approved the final manuscript.

۲۷۵ *Acknowledgment.* We would like to thank all personnel of Mashhad University of Medical Sciences for their
۲۷۶ supports.

۲۷۷

۲۷۸ **References**

- ۲۷۹ 1. Munster VJ, Koopmans M, van Doremalen N, et al. A Novel Coronavirus Emerging in China - Key Questions
۲۸۰ for Impact Assessment. The New England journal of medicine. 2020. doi: 10.1056/NEJMp2000929. PubMed PMID:
۲۸۱ 31978293.
- ۲۸۲ 2. Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New England
۲۸۳ Journal of Medicine. 2020.
- ۲۸۴ 3. Guan W-j, Ni Z-y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England
۲۸۵ Journal of Medicine. 2020. doi: 10.1056/NEJMoa2002032.
- ۲۸۶ 4. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case
۲۸۷ Series. The New England journal of medicine. 2020. doi: 10.1056/NEJMoa2004500.

- 288 5. Liangsheng Zhang F-mSFCZL. Origin and evolution of the 2019 novel coronavirus. *Clinical Infectious Diseases*. 2020. doi: <https://doi.org/10.1093/cid/ciaa112>.
- 289
- 290 6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England)*. 2020;395(10229):1054-62. Epub 2020/03/15. doi: 10.1016/s0140-6736(20)30566-3. PubMed PMID: 32171076.
- 291
- 292 7. Ghinai I, McPherson TD, Hunter JC, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. *The Lancet*. 2020;0(0). doi: 10.1016/S0140-6736(20)30607-3.
- 293
- 294 8. Kelvin DJ, Rubino S. Fear of the novel coronavirus. *The Journal of Infection in Developing Countries*. 2020;14(01):1-2.
- 295
- 296 9. Jin Y, Yang H, Ji W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. *Viruses* 2020, Vol 12, Page 372. 2020;12(4):372-. doi: 10.3390/V12040372.
- 297
- 298 10. McMichael TM, Currie DW, Clark S, et al. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. *New England Journal of Medicine*. 2020:NEJMoa2005412-NEJMoa. doi: 10.1056/NEJMoa2005412.
- 299
- 300 11. Mahase E. China coronavirus: what do we know so far? *BMJ (Clinical research ed)*. 2020;368:m308. doi: 10.1136/bmj.m308.
- 301
- 302 12. de la Cueva-Alique I, Munoz-Moreno L, de la Torre-Rubio E, et al. Water soluble, optically active monofunctional Pd(ii) and Pt(ii) compounds: promising adhesive and antimigratory effects on human prostate PC-3 cancer cells. *Dalton transactions (Cambridge, England : 2003)*. 2019;48(38):14279-93. Epub 2019/09/05. doi: 10.1039/c9dt02873k. PubMed PMID: 31482936.
- 303
- 304 13. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *New England Journal of Medicine*. 2020. doi: 10.1056/NEJMc2001737.
- 305
- 306 14. Liangsheng Zhang F-mSFCZL. Origin and evolution of the 2019 novel coronavirus - Supplementary data. *Clinical Infectious Diseases*. 2020. doi: <https://doi.org/10.1093/cid/ciaa112>.
- 307
- 308 15. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020. doi: 10.1016/S0140-6736(20)30566-3.
- 309
- 310 16. Goshayeshi L, Milani N, Bergquist R, et al. Covid-19 infection without respiratory symptoms: case report of diagnosing a 14 year-old patient with acute abdomen. 2020.
- 311
- 312 17. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020:10.1001/jama.2020.1585. doi: 10.1001/jama.2020.1585. PubMed PMID: 32031570.
- 313
- 314 18. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
- 315
- 316 19. Chen K, Liao QL, Ma ZW, et al. Association of soil arsenic and nickel exposure with cancer mortality rates, a town-scale ecological study in Suzhou, China. *Environmental science and pollution research international*. 2015;22(7):5395-404. Epub 2014/11/21. doi: 10.1007/s11356-014-3790-y. PubMed PMID: 25410308.
- 317
- 318 20. Long B, Brady WJ, Koyfman A, et al. Cardiovascular complications in COVID-19. *The American Journal of Emergency Medicine*. 2020.
- 319
- 320 21. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiology*. 2020. doi: 10.1001/jamacardio.2020.0950.
- 321
- 322 22. Emami A, Javanmardi F, Pirbonyeh N, et al. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. *Archives of Academic Emergency Medicine*. 2020;8(1).
- 323
- 324 23. Bergquist R, Rinaldi L. Covid-19: Pandemonium in our time. *Geospatial health*. 2020;15(1). Epub 2020/04/03. doi: 10.4081/gh.2020.880. PubMed PMID: 32238978.
- 325
- 326 24. Bergquist R SS. COVID-19: end of the beginning? . *Geospat health* 2020;In press.
- 327
- 328 25. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270-3.
- 329
- 330 26. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. *Environmental research*. 2020;188:109890. Epub 2020/08/28. doi: 10.1016/j.envres.2020.109890. PubMed PMID: 32846654; PubMed Central PMCID: PMCPCMC7327471.
- 331
- 332 27. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *Jama*. 2020. Epub 2020/04/07. doi: 10.1001/jama.2020.5394. PubMed PMID: 32250385; PubMed Central PMCID: PMCPCMC7136855.
- 333
- 334
- 335
- 336
- 337
- 338
- 339
- 340
- 341
- 342

343 28. Lippi G, Mattiuzzi C, Sanchis-Gomar F, et al. Clinical and demographic characteristics of patients dying
 344 from COVID-19 in Italy versus China. *Journal of medical virology*. 2020. Epub 2020/04/11. doi: 10.1002/jmv.25860.
 345 PubMed PMID: 32275075.
 346 29. WHO. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease
 347 (COVID-19) 2020 [cited 2020 March 20]. Available from: [https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html)
 348 [guidance-management-patients.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html).
 349 30. Arentz M, Yim E, Klaff L, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19
 350 in Washington State. *JAMA*. 2020. doi: 10.1001/jama.2020.4326.
 351 31. Xu X, Yu C, Qu J, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-
 352 2. *European journal of nuclear medicine and molecular imaging*. 2020;47(5):1275-80. Epub 2020/02/29. doi:
 353 10.1007/s00259-020-04735-9. PubMed PMID: 32107577; PubMed Central PMCID: PMC7080117.
 354 32. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2
 355 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respiratory Medicine*.
 356 2020. doi: [https://doi.org/10.1016/S2213-2600\(20\)30079-5](https://doi.org/10.1016/S2213-2600(20)30079-5).
 357 33. Xiao K, Zhai J, Feng Y, et al. Isolation and characterization of 2019-nCoV-like coronavirus from Malayan
 358 pangolins. *BioRxiv*. 2020.
 359 34. Emami A, Javanmardi F, Pirbonyeh N, et al. Prevalence of Underlying Diseases in Hospitalized Patients with
 360 COVID-19: a Systematic Review and Meta-Analysis. *Archives of academic emergency medicine*. 2020;8(1):e35.
 361 Epub 2020/04/02. PubMed PMID: 32232218; PubMed Central PMCID: PMC7096724.
 362 35. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19)
 363 infection: a systematic review and meta-analysis. *International journal of infectious diseases : IJID : official*
 364 *publication of the International Society for Infectious Diseases*. 2020. Epub 2020/03/17. doi:
 365 10.1016/j.ijid.2020.03.017. PubMed PMID: 32173574.
 366 36. Xiang YT, Jin Y, Wang Y, et al. Tribute to health workers in China: A group of respectable population during
 367 the outbreak of the COVID-19. *International journal of biological sciences*. 2020;16(10):1739-40. Epub 2020/04/01.
 368 doi: 10.7150/ijbs.45135. PubMed PMID: 32226292; PubMed Central PMCID: PMC7098026.
 369 37. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
 370 China. *Lancet*. 2020;395(10223):497-506. Epub 2020/01/28. doi: 10.1016/s0140-6736(20)30183-5. PubMed PMID:
 371 31986264.
 372